… Currently, the goal of chronic myeloid leukemia (CML) treatment is normal survival and good
quality of life without life-long treatment, namely, “treatment-free remission” (TFR). At present…

… Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder characterized by the
presence of the oncogenic BCR-ABL1 fusion gene derived from the reciprocal translocation …

… of interferon-α (IFN-α) as maintenance therapy in patients with favorable-risk acute myeloid
leukemia … : 42 patients who received IFN-α maintenance therapy and 42 patients who did not (…

… -IFN) 30-50µg/week as first line therapy for chronic myeloid leukemia (CML) patients (pts)
in chronic phase and discontinuation of therapy after Peg-IFN maintenance (Figure). Methods…

… We report a high risk chronic myelogenous leukemia (CML) patient harboring the T315I
mutation treated by Interferon-α (INF-α) solo and subsequently combined with dasatinib. …

… effect of interferon-α (IFN-α) in the treatment of MPN has … reticulum staining, or acute myeloid
leukemia (AML) caused by … MPNs include chronic myelogenous leukemia (CML), PV, ET…

… ) and interferon-α have antileukemic and immunostimulatory effects and induce deep
responses in chronic myeloid leukemia (CML). We assigned 40 newly diagnosed chronic-phase …

… discontinuation, 23 patients with chronic myeloid leukemia (CML) in stable complete molecular
response (CMolR) with IFN were revisited. After a median IFN treatment of 105.8 months (…

… -HSCT) recipients, preemptive interferon-α (IFN-α) therapy is considered as a useful method
… assess the long-term efficacy of preemptive IFN-α therapy in acute myeloid leukemia (AML) …

… The tyrosine kinase inhibitors (TKIs) have revolutionized the management of chronic myeloid
leukemia (CML) and BCR-ABL1 inhibitors form the mainstay of CML treatment. Although …